Compare · ALHC vs ILMN
ALHC vs ILMN
Side-by-side comparison of Alignment Healthcare Inc. (ALHC) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALHC and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $40.46B, about 23.9x ALHC ($1.69B).
- ALHC has been more active in the news (9 items in the past 4 weeks vs 8 for ILMN).
- Both have 25 recent analyst ratings on file.
- Company
- Alignment Healthcare Inc.
- Illumina Inc.
- Price
- -
- -
- Market cap
- $1.69B
- $40.46B
- 1M return
- -
- +7.01%
- 1Y return
- -
- +174.89%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2000
- News (4w)
- 9
- 8
- Recent ratings
- 25
- 25
Alignment Healthcare Inc.
Alignment Healthcare, Inc. provides a consumer-centric platform that delivers customized health care to seniors in the United States. It offers medicare advantage plans and health plan options to its partners and patients with customized care and service; and preferred provider organization offerings. The company was founded in 2013 and is based in Orange, California.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest ALHC
- Alignment Health Expands Medicare Advantage Coverage to San Antonio for 2027
- Alignment Healthcare to Announce Third Quarter 2026 Financial Results and Host Conference Call Thursday, Oct. 29, 2026
- Alignment Health Expands Medicare Advantage Coverage to Four New Charlotte-Area Counties for 2027
- Alignment Health Launches New Medicare Advantage Plan Designed for Asian American Seniors in Los Angeles and Orange Counties
- Alignment Healthcare downgraded by William Blair
- SEC Form 8-K filed by Alignment Healthcare Inc.
- SEC Form 4 filed by Alignment Healthcare Inc.
- Alignment Health Expands to Three New California Counties and Adds Hoag and Astrana Health for 2027
- Alignment Health Expands Access to Personalized Senior Care in 2027 with New Markets, Provider Networks and Medicare Advantage Plan Options
- EVP, Corporate Affairs Konowiecki Joseph S sold $202,430 worth of shares (23,511 units at $8.61), decreasing direct ownership by 2% to 1,080,305 units (SEC Form 4) to satisfy tax liability
Latest ILMN
- Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
- SEC Form 8-K filed by Illumina Inc.
- Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Illumina releases SpliceAI2 to help advance rare disease research
- SEC Form 4 filed by Illumina Inc.
- SEC Form SCHEDULE 13G filed by Illumina Inc.
- Director Meister Keith A. was granted 107 shares, increasing direct ownership by 2% to 6,887 units (SEC Form 4)
- Director Ullem Scott B. was granted 113 shares, increasing direct ownership by 1% to 11,143 units (SEC Form 4)
- Chief Legal Officer Coletti Julie Ann was granted 18,763 shares (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 408 shares, decreasing direct ownership by 0.99% to 40,927 units (SEC Form 4)